Total Enterprise Value: Citius Oncology, Inc. (CTOR)
This chart of the market valuation for Citius Oncology, Inc. (CTOR) on the GURU.Markets platform, which stands at 47.28, is based on expectations for future sales of T-cell lymphoma drugs. Current growth is driven by preparations to launch a new skin therapy agent. Meanwhile, the business relies on exclusive FDA rights, which ensure the protection of a niche segment from low-cost generics.
Summary analytical data breakdowns for Citius Oncology, Inc. (CTOR)
Enterprise Value (EV) represents the total buyout price of an asset, combining market capitalization with net debt to determine the actual cost of acquiring a business. Analyzing changes in EV levels allows an investor to promptly identify an overvaluation of Citius Oncology, Inc. (CTOR), whose value depends directly on market confidence in innovative targeted therapies for rare lymphomas.